Cargando…

Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?

The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and treatment provide a basis for clinical decision making. MDS guidelines are issued by expert panels. Our main objective was to exa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasprzak, Annika, Kaivers, Jennifer, Nachtkamp, Kathrin, Haas, Rainer, Kobbe, Guido, Gattermann, Norbert, Germing, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306017/
https://www.ncbi.nlm.nih.gov/pubmed/34300079
http://dx.doi.org/10.3390/ijerph18147629
_version_ 1783727709007904768
author Kasprzak, Annika
Kaivers, Jennifer
Nachtkamp, Kathrin
Haas, Rainer
Kobbe, Guido
Gattermann, Norbert
Germing, Ulrich
author_facet Kasprzak, Annika
Kaivers, Jennifer
Nachtkamp, Kathrin
Haas, Rainer
Kobbe, Guido
Gattermann, Norbert
Germing, Ulrich
author_sort Kasprzak, Annika
collection PubMed
description The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and treatment provide a basis for clinical decision making. MDS guidelines are issued by expert panels. Our main objective was to examine how guidelines influence patients’ adherence to expert recommendations and how they ensure healthcare quality. To approach this question, we reviewed the most common guidelines for diagnosing and treating MDS in adult patients. Furthermore, we critically looked at quality indicators for everyday practice and studied adherence in an everyday outpatient setting. Finally, we also paid close attention to patient-reported outcome measures and studied how they are used as endpoints in clinical trials. We can conclude that the combination of evidence-based diagnostic tools, standardized treatment recommendations, and patient-centered shared decision making will eventually lead to a healthcare standard that will significantly improve outcomes in adult patients with MDS.
format Online
Article
Text
id pubmed-8306017
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83060172021-07-25 Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action? Kasprzak, Annika Kaivers, Jennifer Nachtkamp, Kathrin Haas, Rainer Kobbe, Guido Gattermann, Norbert Germing, Ulrich Int J Environ Res Public Health Review The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and treatment provide a basis for clinical decision making. MDS guidelines are issued by expert panels. Our main objective was to examine how guidelines influence patients’ adherence to expert recommendations and how they ensure healthcare quality. To approach this question, we reviewed the most common guidelines for diagnosing and treating MDS in adult patients. Furthermore, we critically looked at quality indicators for everyday practice and studied adherence in an everyday outpatient setting. Finally, we also paid close attention to patient-reported outcome measures and studied how they are used as endpoints in clinical trials. We can conclude that the combination of evidence-based diagnostic tools, standardized treatment recommendations, and patient-centered shared decision making will eventually lead to a healthcare standard that will significantly improve outcomes in adult patients with MDS. MDPI 2021-07-18 /pmc/articles/PMC8306017/ /pubmed/34300079 http://dx.doi.org/10.3390/ijerph18147629 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kasprzak, Annika
Kaivers, Jennifer
Nachtkamp, Kathrin
Haas, Rainer
Kobbe, Guido
Gattermann, Norbert
Germing, Ulrich
Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
title Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
title_full Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
title_fullStr Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
title_full_unstemmed Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
title_short Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
title_sort guidelines for myelodysplastic syndromes: converting evidence into action?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306017/
https://www.ncbi.nlm.nih.gov/pubmed/34300079
http://dx.doi.org/10.3390/ijerph18147629
work_keys_str_mv AT kasprzakannika guidelinesformyelodysplasticsyndromesconvertingevidenceintoaction
AT kaiversjennifer guidelinesformyelodysplasticsyndromesconvertingevidenceintoaction
AT nachtkampkathrin guidelinesformyelodysplasticsyndromesconvertingevidenceintoaction
AT haasrainer guidelinesformyelodysplasticsyndromesconvertingevidenceintoaction
AT kobbeguido guidelinesformyelodysplasticsyndromesconvertingevidenceintoaction
AT gattermannnorbert guidelinesformyelodysplasticsyndromesconvertingevidenceintoaction
AT germingulrich guidelinesformyelodysplasticsyndromesconvertingevidenceintoaction